Upstream Bio Inc. (NASDAQ: UPB) reported new data from its Phase 2 VIBRANT trial showing that 79% of participants treated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE